| 198 | 0 | 137 |
| 下载次数 | 被引频次 | 阅读次数 |
目前基于规律成簇的间隔短回文重复（Clustered regularly interspaced short palindromic repeats, CRISPR）/CRISPR相关蛋白（Cas）系统的基因治疗在遗传病、肿瘤及感染性疾病等领域均取得重大突破，其中Cas13a属于VI型CRISPR系统，Cas13a蛋白在HIV感染细胞内crRNA的引导下定位目标RNA，切割核酸，同时激活Cas13a蛋白的附属效应（Collateral effect）可高效切割细胞内非特异性单链RNA，从而诱导感染细胞凋亡，进一步破坏病毒库，是最有可能功能性治愈HIV的策略。本研究旨在筛选靶向HIV-1的高灵敏度crRNA，进一步探索组合不同crRNA对HIV-1的抑制效果，并在细胞转染水平证明Cas13a/crRNA系统的附属切割活性及其诱导细胞凋亡。在LANL数据库中比对HIV-1各亚型毒株序列，获得各功能蛋白高度保守区。同时，结合HIV数据库中RNA的剪接供体及受体位点信息；然后利用MPRDOCK软件进行crRNA与LwCas13a的分子对接并计算结合复合物的自由能大小选定一组crRNA池；再以荧光标记RNA探针与LwCas13a蛋白组成可视化检测体系，以FAM荧光信号强弱确定了最有效的crRNA。构建LwCas13a和crRNA的共表达质粒，通过共转染HIV全长感染性克隆质粒和含单个或多个crRNA组合的LwCas13a的表达质粒到HEK293T细胞中，根据转染细胞及其上清再感染细胞中萤光素酶和病毒结构蛋白RNA表达水平来判定CRISPR-Cas13a系统对HIV基因表达的抑制效率。初步筛选出优选的27条crRNA并结合切割荧光强弱从中筛选出8条高灵敏度crRNA。细胞共转染实验表明，靶向病毒结构基因的单个crRNA,crGag2,crPol1,crA53能降低HIV-1子代病毒RNA表达降低了43.2%～58.3%，同样，再次感染实验也证明子代病毒活性滴度降低了38%～74.6%。进一步的结果证明，4个crRNA(crD15,crA53,crGag2,crPol1)联用比单个crRNA表达降低了86.4%，比两个crRNAs降低了64.9%，同时在共转染HEK293T细胞中观察到Cas13a蛋白的附属切割活性及其诱导细胞凋亡。我们建立的CRISPR/Cas13a系统能够显著抑制HIV病毒复制和子代病毒产生并诱导细胞凋亡，为HIV的治疗提供了一种新的工具。
Abstract：Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein(CRISPR/Cas) systems have recently become widely used in research for generating potential therapeutic tools as well as for muscular dystrophy, infectious diseases(e. g., malaria), and complex diseases(e. g., cancer). Cas13a belongs to the class-2 type-VI CRISPR-Cas system, which exhibits two distinct ribonuclease activities. Cas13a possesses sequence-specific RNA-cleavage activity in human immunodeficiency virus(HIV)-infected cells under the guidance of the CRISPR-RNA(crRNA) complementary sequence to the interested site. After specific cleavage, Cas13a activates collateral cleavage activity towards adjacent non-specific single-stranded RNA sequences, which can induce the apoptosis of the infected virus and decrease the production of the progeny virus. Therefore, with purging of the viral reservoir, it is the most probable strategy for the functional cure of HIV infection. We screened high-sensitivity crRNA targeting HIV-1 and determined anti-HIV activity by a combination of multiple crRNAs. Meanwhile, the collateral cleavage activity of Cas13a/crRNA and apoptosis were measured in HEK293T transiently transfected plasmids encoding Cas13a, Nl4-nanoLuc, and targeting crRNAs. HIV-1 sequences from different types were aligned in the LANL database. Regions with high identity were selected for designing crRNA. Then, a set of crRNA candidates was chosen by molecular docking of crRNA and LwCas13a using MPRDOCK software. crRNA/Cas13a with the lowest binding free energy was selected for further analyses. Next, a visual detection system was established by combination of a RNA probe labeled with 5'-FAM and 3'-BHQ1, with LwCas13a protein. The FAM fluorescence signal was used to determine which crRNAs were the most effective. Single crRNA was inserted into the expression vector of LwCas13a and the resultant plasmids verified by sequencing. Their constructs were co-transfected into HEK293T cells with HIV-1 full-length infectious clone plasmids. This supernatant was collected and used to infect new Tzm-bl cells. The viral RNA expression and luciferase activity of transfected and infected cells were determined for evaluation of antiviral activity of the CRISPR-Cas13a/crRNA system. Based on the intensity of the fluorescence signal, eight highly sensitive crRNAs were identified from a pool of 27 favored crRNAs. Cotransfection of HEK293T cells indicated that individual crRNAs targeting viral function-related genes(crGag2, crPol, and crA53) could decrease HIV-1 RNA from 43.2% – 58.3%. Meanwhile, analyses of infectious viral titers in the supernatant of Tzm-bl cells revealed that the viral infectivity from CRISPR-Cas13a/crRNA-treated cell decreased 38% – 74.6% compared with that in an untreated panel. Combination of the four crRNAs(crD15, crA53, crGag2, crPol1) could reduce HIV RNA expression by 86.4% and 64.9% compared with that using single crRNA and two crRNAs during co-transfection of HEK293T cells. Meanwhile, the collateral cleavage activity of Cas13a protein and apoptosis were observed in transfected HEK293T cells with plasmids encoding Nl4-3 and CRISPR-Cas13a/crRNA. Our results demonstrate that the CRISPR-Cas13a system is a novel and effective technology to inhibit HIV replication. This programmable method could be developed further into a novel therapeutic strategy for HIV and other RNA viruses.
[1] Collaboration A T C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013:a collaborative analysis of cohort studies[J]. Lancet HIV,2017, 4(8):e349-e356. DOI:10.1016/S2352-3018(17)30066-8.
[2] Siliciano J D, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+T cells[J]. Nat Med, 2003, 9(6):727-728. DOI:10.1038/nm880.
[3] Wagner T A, McLaughlin S, Garg K, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection[J].Science, 2014, 345(6196):570-573. DOI:10.1126/science.1256304.
[4] Maldarelli F, Wu X, Su L, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells[J]. Science, 2014, 345(6193):179-183. DOI:10.1126/science.1254194.
[5] Pennings P S. HIV Drug Resistance:Problems and Perspectives[J]. Infect Dis Rep, 2013, 5(Suppl 1):e5.DOI:10.4081/idr.2013.s1.e5.
[6] Kordelas L, Verheyen J, Beelen D W, et al. Shift of HIV tropism in stem-cell transplantation with CCR5Delta32 mutation[J]. N Engl J Med, 2014, 371(9):880-882. DOI:10.1056/NEJMc1405805.
[7] Gupta R K, Abdul-Jawad S, McCoy L E, et al. HIV-1remission following CCR5Delta32/Delta32haematopoietic stem-cell transplantation[J]. Nature,2019, 568(7751):244-248. DOI:10.1038/s41586-019-1027-4.
[8] Xu L, Wang J, Liu Y, et al. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia[J]. N Engl J Med, 2019, 381(13):1240-1247. DOI:10.1056/NEJMoa1817426.
[9] Kessing C F, Nixon C C, Li C, et al. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a"Block-and-Lock"Strategy for HIV-1 Treatment[J]. Cell Rep, 2017, 21(3):600-611. DOI:10.1016/j.celrep.2017.09.080.
[10]Borducchi E N, Cabral C, Stephenson K E, et al.Ad26/MVA therapeutic vaccination with TLR7stimulation in SIV-infected rhesus monkeys[J]. Nature,2016, 540(7632):284-287. DOI:10.1038/nature20583.
[11]Tebas P, Jadlowsky J K, Shaw P A, et al. CCR5-edited CD4+T cells augment HIV-specific immunity to enable post-rebound control of HIV replication[J]. J Clin Invest, 2021, 131(7). DOI:10.1172/JCI144486.
[12]Roberts M R, Qin L, Zhang D, et al. Targeting of human immunodeficiency virus-infected cells by CD8+T lymphocytes armed with universal T-cell receptors[J]. Blood, 1994, 84(9):2878-2889. DOI:10.1182/blood.V84.9.2878.bloodjournal8492878.
[13]Frangoul H, Altshuler D, Cappellini M D, et al.CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia[J]. N Engl J Med, 2021, 384(3):252-260. DOI:10.1056/NEJMoa2031054.
[14]Yin D, Ling S, Wang D, et al. Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice[J]. Nat Biotechnol, 2021, 39(5):567-577. DOI:10.1038/s41587-020-00781-8.
[15]Lee R G, Mazzola A M, Braun M C, et al. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models[J]. Circulation, 2023, 147(3):242-253.DOI:10.1161/CIRCULATIONAHA.122.062132.
[16]Maeder M L, Stefanidakis M, Wilson C J, et al.Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10[J]. Nat Med, 2019, 25(2):229-233. DOI:10.1038/s41591-018-0327-9.
[17]Mancuso P, Chen C, Kaminski R, et al. CRISPR based editing of SIV proviral DNA in ART treated non-human primates[J]. Nat Commun, 2020, 11(1):6065. DOI:10.1038/s41467-020-19821-7.
[18]Abudayyeh O O, Gootenberg J S, Konermann S, et al.C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector[J]. Science, 2016,353(6299):aaf5573. DOI:10.1126/science.aaf5573.
[19]East-Seletsky A, O'Connell M R, Burstein D, et al.RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes[J]. Mol Cell, 2017, 66(3):373-383 e373. DOI:10.1016/j.molcel.2017.04.008.
[20]Liu L, Li X, Wang J, et al. Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities[J]. Cell,2017, 168(1-2):121-134 e112. DOI:10.1016/j.cell.2016.12.031.
[21]Gootenberg J S, Abudayyeh O O, Lee J W, et al.Nucleic acid detection with CRISPR-Cas13a/C2c2[J].Science, 2017, 356(6336):438-442. DOI:10.1126/science.aam9321
[22]Ackerman C M, Myhrvold C, Thakku S G, et al.Massively multiplexed nucleic acid detection with Cas13[J]. Nature, 2020, 582(7811):277-282. DOI:10.1038/s41586-020-2279-8.
[23]Gootenberg J S, Abudayyeh O O, Kellner M J, et al.Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6[J]. Science, 2018, 360(6387):439-444. DOI:10.1126/science.aaq0179.
[24]Abudayyeh O O, Gootenberg J S, Essletzbichler P, et al. RNA targeting with CRISPR-Cas13[J]. Nature,2017, 550(7675):280-284. DOI:10.1038/nature24049.
[25]Konermann S, Lotfy P, Brideau N J, et al.Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors[J]. Cell, 2018, 173(3):665-676 e614. DOI:10.1016/j.cell.2018.02.033.
[26]Aman R, Ali Z, Butt H, et al. RNA virus interference via CRISPR/Cas13a system in plants[J]. Genome Biol,2018, 19(1):1. DOI:10.1186/s13059-017-1381-1.
[27]Jing X, Xie B, Chen L, et al. Implementation of the CRISPR-Cas13a system in fission yeast and its repurposing for precise RNA editing[J]. Nucleic Acids Res, 2018, 46(15):e90. DOI:10.1093/nar/gky433.
[28]Kushawah G, Hernandez-Huertas L, Abugattas-Nunez Del Prado J, et al. CRISPR-Cas13d Induces Efficient mRNA Knockdown in Animal Embryos[J]. Dev Cell,2020, 54(6):805-817 e807. DOI:10.1016/j.devcel.2020.07.013.
[29]Abbott T R, Dhamdhere G, Liu Y, et al. Development of CRISPR as an Antiviral Strategy to Combat SARSCoV-2 and Influenza[J]. Cell, 2020, 181(4):865-876e812. DOI:10.1016/j.cell.2020.04.020.
[30]Li S, Li X, Xue W, et al. Screening for functional circular RNAs using the CRISPR-Cas13 system[J]. Nat Methods, 2021, 18(1):51-59. DOI:10.1038/s41592-020-01011-4.
[31]Xu C, Zhou Y, Xiao Q, et al. Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes[J]. Nat Methods, 2021, 18(5):499-506. DOI:10.1038/s41592-021-01124-4.
[32]Li H, Wang S, Dong X, et al. CRISPR-Cas13a Cleavage of Dengue Virus NS3 Gene Efficiently Inhibits Viral Replication[J]. Mol Ther Nucleic Acids, 2020, 19(2162-2531(Print)):1460-1469. DOI:10.1016/j.omtn.2020.01.028.
[33]Yin L, Zhao F, Sun H, et al. CRISPR-Cas13a Inhibits HIV-1 Infection[J]. Mol Ther Nucleic Acids, 2020, 21(2162-2531(Print)):147-155. DOI:10.1016/j.omtn.2020.05.030.
[34]Nguyen H, Wilson H, Jayakumar S, et al. Efficient Inhibition of HIV Using CRISPR/Cas13d Nuclease System[J]. Viruses, 2021, 13(9):1850. DOI:10.3390/v13091850.
[35]Nunes-Alves C. Viral infection:Seeding the HIV-1reservoir[J]. Nat Rev Microbiol, 2014, 12(9):594.DOI:10.1038/nrmicro3342.
[36]Whitney J B, Hill A L, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys[J]. Nature, 2014, 512(7512):74-77.DOI:10.1038/nature13594.
[37]Landovitz R J, Scott H, Deeks S G. Prevention,treatment and cure of HIV infection[J]. Nat Rev Microbiol, 2023, 21(10):657-670. DOI:10.1038/s41579-023-00914-1.
[38]Gaebler C, Nogueira L, Stoffel E, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy[J].Nature, 2022, 606(7913):368-374. DOI:10.1038/s41586-022-04597-1.
[39]Niessl J, Baxter A E, Mendoza P, et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity[J]. Nat Med, 2020, 26(2):222-227. DOI:10.1038/s41591-019-0747-1.
[40]Gunst J D, Pahus M H, Rosas-Umbert M, et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1:a phase 1b/2a, randomized trial[J]. Nat Med, 2022, 28(11):2424-2435. DOI:10.1038/s41591-022-02023-7.
[41]Yukl S A, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions:a study of the Berlin patient[J]. PLoS Pathog, 2013, 9(5):e1003347. DOI:10.1371/journal.ppat.1003347.
[42]Wu Y, Jin W, Wang Q, et al. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma[J]. Mol Ther, 2021, 29(11):3305-3318.DOI:10.1016/j.ymthe.2021.07.002.
[43]Tong H, Huang J, Xiao Q, et al. High-fidelity Cas13variants for targeted RNA degradation with minimal collateral effects[J]. Nat Biotechnol, 2023, 41(1):108-119. DOI:10.1038/s41587-022-01419-7.
[44]Wang D, Zhang F, Gao G. CRISPR-Based Therapeutic Genome Editing:Strategies and In Vivo Delivery by AAV Vectors[J]. Cell, 2020, 181(1):136-150. DOI:10.1016/j.cell.2020.03.023.
[45]Wang D, Tai P W L, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery[J]. Nat Rev Drug Discov, 2019, 18(5):358-378. DOI:10.1038/s41573-019-0012-9.
[46]Cecchin R, Troyer Z, Witwer K, et al. Extracellular vesicles:The next generation in gene therapy delivery[J]. Mol Ther, 2023, 31(5):1225-1230. DOI:10.1016/j.ymthe.2023.01.021.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004496
中图分类号:R512.91
引用信息:
[1]王涛,夏学娇,马妍等.靶向HIV-1的Cas13a/crRNA的快速筛选和抗病毒活力测定[J].病毒学报,2024,40(05):996-1009.DOI:10.13242/j.cnki.bingduxuebao.004496.
基金信息:
国家科技重大专项（项目号：2017ZX10202102-007）,题目：艾滋病和病毒性肝炎等重大传染病防治; 湖北省自然科学基金计划面上类项目（项目号：2019CFB529）,题目：潜伏性病毒激活剂联合CAR-T细胞清除体内HIV病毒“储藏库”的研究~~